| Document Date: 2011-08-15 11:58:23
Open Document File Size: 12,69 KBShare Result on Facebook
City Bad Krozingen / MOUNTAIN VIEW / Leipzig / / Company NovoStent Corporation / / Country Germany / / Event FDA Phase / / IndustryTerm treatment of femoropopliteal disease / helical stent technology / vascular device / treatment of superficial femoral and popliteal artery disease / nitinol device / metal surface area / / MedicalCondition pain / femoropopliteal disease / aneurysm / disease / peripheral artery disease / atherosclerotic disease / leg pain / superficial femoral and popliteal artery disease / small vessel disease / / Person G. Ray Martin / Sven Braunlich / Thomas Zeller / / Position Director of the Department / Professor / President and CEO / / Product SAMBATM Stent / / ProvinceOrState California / / Technology helical stent technology / /
SocialTag |
NovoStent Announces Completion of Enrollment in SAMBA Femoropopliteal Trial MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)—September 18, 2009--NovoStent Corporation, a privately held medical device company, today announced the